News | January 26, 2022
Astec LifeSciences Q3FY22 PAT at Rs 24.74 cr.
Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021
Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021
After double lung transplantation, he was discharged without supplemental oxygen on the eleventh day
Acute therapies continue to report strong growth compared to chronic ones.
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
When the Delfi technology was used as a pre-screen to determine if a low dose CT (LDCT), should be performed, the combined approach led to the detection of 90% of lung cancers, including 80% of stage I cancers
A treatment to prevent extreme symptoms and cut hospitalisation
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company is doubling its chemistry research capacity that should commission by Q2'FY22
Subscribe To Our Newsletter & Stay Updated
